Skip to main content
. Author manuscript; available in PMC: 2014 Nov 22.
Published in final edited form as: Nature. 2014 Apr 9;509(7501):492–496. doi: 10.1038/nature13180

Figure 3. Genetic ablation of Ctr1 decreases MAPK signaling and tumorigenesis and extends the lifespan in a mouse model of BrafV600E-driven lung cancer.

Figure 3

a, Representative resected (arrows: visible lesions, scale bar: 1cm) c, H&E stained (scale bar: 1mm) or e, immunohistochemical detection of P-ERK1/2 (red: positive pixels, scale bar: 500μm) of lungs of Ctr1+/+ or Ctr1flox/flox BP mice (a,c fixed or e, moribundity endpoint). b, Box and whiskers plot of tumors/mouse (n=5 lungs) d, mean % of area of abnormal lung tissue (n=5 lungs) and f, mean % P-ERK1/2 positive-staining area/lung tumor from Ctr1+/+ (n=199 tumors) versus Ctr1flox/flox (n=142 tumors) BP mice (b,d fixed or f, moribundity endpoint). g, Kaplan-Meier survival analysis of Ctr1+/+ (black line, n=30) versus Ctr1flox/flox (red line, n=30) BP mice. * P<0.05. ** P<0.01. ***P<0.001. ****P<0.0001.